Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
Lawrence Fong, MD, of the University of California, San Francisco, discusses combination immunotherapy, now approved in melanoma, and the trials underway to explore other indications.
Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses a way to promote functional persistence of CAR T cells as an ideal strategy for solid tumor immunotherapy.
Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their antitumor activity in solid tumors.
Holger N. Lode, MD, of the University of Greifswald, discusses the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor genotypes and Fc-receptor polymorphisms. (Abstract 111)
Elizabeth Ann Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses some of the top papers presented at the ASCO-SITC Symposium and how these presentations will affect clinical practice.
